Disposable dry powder inhaler developer 1nhaler has announced the appointment of former AstraZeneca VP Jane Gaddum as Board Chair and non-executive director and former GSK VP Gordon Muirhead as a non-executive director. Gaddum was AstraZeneca VP of Global Marketing for Emerging Respiratory and Inflammation from 1997 to 2013, according to her LinkedIn profile. Muirhead, who is currently President of GMPharma Limited, was VP of new product introduction at GSK from 1998 to 2017 and has served as an adviser to 1nhaler since it was founded in 2017.
In November 2023, 1nhaler announced that it had raised £2million for development of its cardboard DPI device. The company says that it will also receive an R&D grant worth £765,000 from Scottish Enterprise and plans to initiate clinical trials in 2025.
1nhaler CEO Lisa McMyn commented, “Jane and Gordon’s combined experience in bringing several market-leading inhalation devices to market will be invaluable as we look to accelerate product development and deliver on our ambition to create the industry’s smallest, simplest and most sustainable single-dose inhaler.”
Read the 1nhaler press release.
